Live
- Nagarjuna appears cool and suave in ‘Kubera’ first look
- Yerragondapalem: Manda Krishna seeks votes for Modi, Naidu
- Eluru: Poll observers inspect election counting centre
- YS Jaganmohan Reddy to Lead Election Campaign in Three Constituencies
- New Delhi: 400 a joke, 300 impossible, 200 challenge for BJP says Shashi Tharoor
- Minorities’ welfare possible with TDP: Nazeer
- Rajamahendravaram: Police seize Rs 2.4 cr from private bus
- Audimulapu urges people to make Jagan CM again
- New Delhi: ‘Senders’ intention was to create mass panic’
- Tim Cook Teases Apple's Generative AI Plans, New Announcements Coming Soon
Roche Pharma enters ophthalmology segment
Hyderabad: Roche Pharma India, a wholly-owned subsidiary of Switzerland-headquartered healthcare company Roche, on Tuesday announced its foray into...
Hyderabad: Roche Pharma India, a wholly-owned subsidiary of Switzerland-headquartered healthcare company Roche, on Tuesday announced its foray into the Ophthalmology space with the official launch of Vabysmo (faricimab), an antibody injection for the treatment of two causes of vision loss.
According to Roche, more than 75 million patients globally and seven million patients in India suffer from retinal vision loss, wherein India is home to one-third of the blind population of the world. Furthermore, in India, Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) cases stands at around 3.30 lakh.
Vabysmo, an injectable eye medicine was launched earlier this year in the Indian market. The drug is manufactured in Switzerland.
Bhavesh Shah from Roche Pharma India, present virtually from Gujarat for the launch, said that the pharma major has adopted three-point strategy for commercialisation of the product which includes creating awareness about their product, collaboration to drive diagnosis, and specialistsreferring Vabysmo.
